Columvi achieved a 78.3% complete response rate and 85% overall response rate in relapsed/refractory mantle cell lymphoma patients. Cytokine release syndrome occurred in 70% of patients, with lower ...

Atezolizumab showed modest response rates in NSCLC patients previously treated with PD-1 inhibitors, with a suggested baseline response rate of 10% for new ICI combinations. The study's primary ...

Please provide your email address to receive an email when new articles are posted on . Furthermore, a study Kerschbaumer had previously co-authored found that placebo-treated patients on background ...

Please provide your email address to receive an email when new articles are posted on . Dostarlimab conferred clinical complete responses in all patients treated during a phase 2 trial.. Circulating ...

On August 28,2025, NASS announced the cancellation of the Farm Labor Survey. The discontinuance was officially posted to the Federal Register on September 3. Countless stakeholders including farmers, ...

BARCELONA — Restarting an anti-CGRP monoclonal antibody (mAb) for migraine prevention after a gap in treatment often leads to a lower efficacy rate in the second treatment period, a new study suggests ...

Role of induction chemotherapy in locally advanced oropharyngeal carcinoma in Indian population. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a ...

Zongertinib shows a 71% response rate and 12.4 months median progression-free survival in HER2-mutated NSCLC, with minimal adverse events. Patient-reported outcomes indicate rapid improvement in ...

Xilio Therapeutics reports 26% response rate for vilastobart and atezolizumab in metastatic MSS CRC patients, with favorable safety profile. Xilio Therapeutics has reported promising results from its ...

Administrators should give instructors and students clear, visible examples of how course evaluation data has been used to improve the unit's programs, teaching and facilities. Instructors can ...